|

Domvanalimab Clinical Trials

4 actively recruiting trials across 3 locations

Also known as: AB154

Pipeline

Phase 2: 3Phase 3: 1

Top Sponsors

  • Gilead Sciences1
  • Fundación para el Progreso de la Oncología en Cantabria1
  • Diwakar Davar1
  • AstraZeneca1

Indications

  • Cancer4
  • Urothelial Bladder Carcinoma1
  • Metastatic Urothelial Cancer1
  • Melanoma1
  • Lung Cancer1

Other1 trial

PeRioperative Immunotherapy Combined With Sacituzumab Govitecan in Muscle Invasive blAdder Cancer
Phase 2

Chandler, Arizona1 trial

A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC

Research Site

Phase 3

Tucson, Arizona1 trial

Study of Sacituzumab Govitecan in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread

The University of Arizona Cancer Center-North Campus

Phase 2

Pittsburgh, Pennsylvania1 trial

Zimberelimab (AB122) With TIGIT Inhibitor Domvanalimab (AB154) in PD-1 Relapsed/Refractory Melanoma

UPMC Hillman Cancer Center

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.